Research and Markets: European Nuclear Medicine / Radiopharmaceuticals Market - Global Trends & Forecasts to 2017

Tue Apr 9, 2013 1:40pm EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130409:nBw096456a

DUBLIN--(Business Wire)--

Research and Markets

has announced the addition of the "European Nuclear Medicine /
Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)],
[Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology,
Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecas" report
to their offering. 

The European radioisotopes market was valued at $1.1 billion in 2012 and is
poised to reach $1.6 billion in 2017 at a CAGR of 6.8%. 

A study conducted by Organization for Economic Co-operation and Development
(OECD) estimates that Tc-99m diagnostic procedures are expected to increase by
15% to 20% in mature markets such as Europe, and other developed regions between
2010 and 2030. Radiopharmaceuticals in neurological applications such as
Alzheimer's disease, Parkinson's disease, and dementia are also being preferred
by practitioners besides conventional treatment. Further, upcoming radioisotopes
such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical
applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in
France in 2018 is, however, a major threat for manufacturers. 

The therapy market is predominantly driven by its oncologic applications. Since
conventional treatment procedures of cancer, surgery and chemotherapy have
significant side effects, radioisotopes are being preferred by medical
practitioners due to minimum or no side effects. The radiopharmaceutical therapy
market is expected to grow significantly with the launch of the much-desired
Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to
take up market share of beta emitters and brachytherapy. 

The radioisotope and stable isotope markets have been segmented according to the
type of isotope, and applications. Both of these markets are broken down into
segments and sub-segments, providing exhaustive value analysis for the years
2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed
at a granular level by geography (North America, Europe, Asia, and Rest of the
World) to provide in-depth information on the European scenario.

Key Topics Covered:

1 Key Take-Aways 

2 Executive Summary 

3 Market Overview 

4 European Radiopharmaceuticals Market, By Isotope 

5 European Radiopharmaceuticals Market,By Application/Indication 

6 European Enriched Stable Isotopes Market 

7 Geographic Analysis 

8 Competitive Landscape 

9 Company Profiles

Companies Mentioned

- Bracco Imaging S.P.A. 

- Cambridge Isotope Laboratories, Inc. 

- Cardinal Health, Inc. 

- Covidien, Plc 

- Eczacibasi-Monrol 

- Fujifilm Holdings Corporation 

- Ge Healthcare (Subsidiary Of General Electric Company) 

- Iba Group 

- Isotec, Inc. (Sigma-Aldrich) 

- Lantheus Medical Imaging, Inc. 

- Nordion, Inc. 

- Ntp Radioisotopes (Pty), Ltd. 

- Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.) 

- Rotem Industries, Ltd., Inc. 

- Taiyo Nippon Sanso Corporation 

- Urenco Limited 

For more information visit Research and Markets

About Research and Markets

Research and Markets is the world's leading source for international market
research reports and market data. We provide you with the latest data on
international and regional markets, key industries, the top companies, new
products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.